Pharmaceutical

Boehringer and 3T Biosciences partner to develop cancer immunotherapies

Boehringer Ingelheim has signed a deal with 3T Biosciences for the discovery and development of next-generation cancer immunotherapies.

Jan 5, 2024 - 18:00
Boehringer and 3T Biosciences partner to develop cancer immunotherapies
Boehringer Ingelheim has signed a deal with 3T Biosciences for the discovery and development of next-generation cancer immunotherapies.
Read the original article

Tags:

Previous Article

Rhythm expands obesity portfolio with Phase II weight loss drug for $100m

Next Article

Avistone raises $140m to support drug research and development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CD70 CAR-T by UTC Therapeutics for Mantle Cell Lymphoma...

Aug 10, 2023

STAT+: Another powerful congressional committee is ready to take on PBMs

STAT+: Another powerful congressional committee is read...

Apr 27, 2023

Blue Earth and Seibersdorf expand radiopharmaceutical manufacture deal

Blue Earth and Seibersdorf expand radiopharmaceutical m...

Aug 13, 2024